These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8562545)

  • 1. Use of perfluorocarbon liquids in proliferative vitreoretinopathy: results and complications.
    Stolba U; Binder S; Velikay M; Datlinger P; Wedrich A
    Br J Ophthalmol; 1995 Dec; 79(12):1106-10. PubMed ID: 8562545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perfluoroperhydrophenanthrene versus perfluoro-n-octane in vitreoretinal surgery.
    Loewenstein A; Humayun MS; de Juan E; Campochiaro PA; Haller JA
    Ophthalmology; 2000 Jun; 107(6):1078-82. PubMed ID: 10857826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Vitrectomy in proliferative vitreoretinopathy. Anatomical and functional results in 501 patients].
    Körner F; Böhnke M
    Klin Monbl Augenheilkd; 1995 Apr; 206(4):239-45. PubMed ID: 7791283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Application of perfluorocarbon liquids in vitrectomy].
    Jiang Y; Li X; Ye C
    Zhonghua Yan Ke Za Zhi; 1999 Jan; 35(1):33-5. PubMed ID: 11835771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term comparative anatomic results of retinal detachment with vitreoretinal proliferation operated with or without using liquid perfluorocarbons].
    Behar-Cohen F; Le Rouic JF; Chauvaud D
    J Fr Ophtalmol; 1999 Oct; 22(8):853-8. PubMed ID: 10572796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of relaxing retinotomy on surgical outcomes in proliferative vitreoretinopathy.
    Tseng JJ; Barile GR; Schiff WM; Akar Y; Vidne-Hay O; Chang S
    Am J Ophthalmol; 2005 Oct; 140(4):628-36. PubMed ID: 16226515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does the presence of heparin and dexamethasone in the vitrectomy infusate reduce reproliferation in proliferative vitreoretinopathy?
    Williams RG; Chang S; Comaratta MR; Simoni G
    Graefes Arch Clin Exp Ophthalmol; 1996 Aug; 234(8):496-503. PubMed ID: 8858355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for retention of subretinal perfluorocarbon liquid in vitreoretinal surgery.
    Garcia-Valenzuela E; Ito Y; Abrams GW
    Retina; 2004 Oct; 24(5):746-52. PubMed ID: 15492629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relaxing retinopathies and liquid perfluorocarbons].
    Morel C; Doan S; Rivoal O; Ameline B; Monin C; Larricart P
    J Fr Ophtalmol; 1998 May; 21(5):315-20. PubMed ID: 9759424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitrectomy with short term postoperative tamponade using perfluorocarbon liquid for giant retinal tears.
    Sirimaharaj M; Balachandran C; Chan WC; Hunyor AP; Chang AA; Gregory-Roberts J; Hunyor AB; Playfair TJ
    Br J Ophthalmol; 2005 Sep; 89(9):1176-9. PubMed ID: 16113376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anatomy and function of the macula in patients after retinectomy for retinal detachment complicated by proliferative vitreoretinopathy.
    Stopa M; Kociecki J
    Eur J Ophthalmol; 2011; 21(4):468-72. PubMed ID: 21140368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors, anatomical, and visual outcomes of injured eyes with proliferative vitreoretinopathy: eye injury vitrectomy study.
    Feng K; Hu Y; Wang C; Shen L; Pang X; Jiang Y; Nie H; Wang Z; Ma Z
    Retina; 2013 Sep; 33(8):1512-8. PubMed ID: 23538583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional outcome and prognostic factors in 304 eyes managed by retinectomy.
    Grigoropoulos VG; Benson S; Bunce C; Charteris DG
    Graefes Arch Clin Exp Ophthalmol; 2007 May; 245(5):641-9. PubMed ID: 17119994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BLINDNESS RELATED TO PRESUMED RETINAL TOXICITY AFTER USING PERFLUOROCARBON LIQUID DURING VITREORETINAL SURGERY.
    Méndez-Martínez S; Calvo P; Rodriguez-Marco NA; Faus F; Abecia E; Pablo L
    Retina; 2018 Sep; 38(9):1856-1864. PubMed ID: 28723847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Retinectomy in Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy.
    Naz S; Rizvi SF; Murtaza F; Shehzadi B
    J Coll Physicians Surg Pak; 2018 Nov; 28(11):848-852. PubMed ID: 30369377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of postoperative lens status on intraocular pressure in proliferative vitreoretinopathy.
    Tseng JJ; Schiff WM; Barile GR; Biscette O; Williams SL; Cekic O; Dhrami-Gavazi E; Chang S
    Am J Ophthalmol; 2009 May; 147(5):875-85, 885.e1-2. PubMed ID: 19193362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of vitrectomy with inferior retinectomy in patients with recurrent rhegmatogenous retinal detachments and proliferative vitreoretinopathy.
    Quiram PA; Gonzales CR; Hu W; Gupta A; Yoshizumi MO; Kreiger AE; Schwartz SD
    Ophthalmology; 2006 Nov; 113(11):2041-7. PubMed ID: 16952397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inferior retinotomy and silicone oil tamponade for recurrent inferior retinal detachment and grade C PVR in eyes previously treated with pars plana vitrectomy or scleral buckle.
    Mancino R; Aiello F; Ciuffoletti E; Di Carlo E; Cerulli A; Nucci C
    BMC Ophthalmol; 2015 Dec; 15():173. PubMed ID: 26645589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Retinectomies in the treatment of retinal detachments with vitreoretinal proliferation].
    Metge F; Massin P; Gaudric A
    J Fr Ophtalmol; 1997; 20(5):345-9. PubMed ID: 9238471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery.
    Tseng W; Cortez RT; Ramirez G; Stinnett S; Jaffe GJ
    Am J Ophthalmol; 2004 Jun; 137(6):1105-15. PubMed ID: 15183797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.